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SUPPLEMENTARY MATERIALS AND METHODS 
Cell culture 
The BE(2)-C cell line was obtained from ECACC (Salisbury, UK) and the IMR-32, Kelly 
and SH-SY5Y cell lines from the DSMZ (Braunschweig, Germany). SH-EP and the synthetic 
MYCN-inducible SH-EP Tet-21/N cell model [1] were kindly provided by M. Schwab. 
BE(2)-C, IMR-32, Kelly and SH-SY5Y were cultured in DMEM (Lonza) supplemented with 
10% FCS (Sigma-Aldrich) and 1% NEAA (Lonza) at 37° C and 5% CO2. SH-EP was cul-
tured in RPMI 1640 Medium (Lonza) supplemented with 10% FCS and 1% NEAA at 37° C 
and 5% CO2. SH-EP Tet-21/N cells were cultured in RPMI 1640 medium with HEPES (Lon-
za) supplemented with 10% FCS, 1% NEAA, 200µg/ml G418 (Merck Millipore) and 
100µg/ml hygromycin B (Sigma-Aldrich), and treated with 1µg/ml tetracycline (AppliChem) 
to suppress synthetic MYCN expression [1]. The stable CD9-inducible model was generated 
by electroporating pcDNA™6/TR (Invitrogen) and pT-Rex™-DEST30-CD9 (RefSeq 
NM_001769; Invitrogen) into SH-EP cells, with control cells containing pcDNA™6/TR and 
pT-Rex™-DEST30. Selection medium contained 7.5µg/ml blasticidin and 0.5mg/ml geneti-
cin, and single-cell clones were obtained by limited dilution. CD9 expression was induced by 
1µg tetracycline/ml medium, and the clone with the strongest CD9 induction was identified 
by western blotting and flow cytometry (Supplementary Figure S3A-B). Cell lines were 
monitored for infections by high-throughput multiplex cell contamination testing [2]. Cell line 
authenticity was validated by high-throughput SNP-based assays [3]. 
Reagents 
Stock solutions of 5-Aza-2’-deoxycytidine (10 mM; Sigma-Aldrich), panobinostat (1 mM; 
Selleck Chemicals), vorinostat (1 mM; Chemos), compound 2 (250 mM; Merck Millipore), 
tubacin (1 mM; Selleck Chemicals) and bufexamac (100 mM; Sigma-Aldrich) were prepared 
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in DMSO [4]. Actinomycin D (stock solution 5 mg/ml in DMSO; Sigma-Aldrich) was added 
at a final concentration of 1µg/ml to the medium [4]. 
Transfection of siRNAs, shRNA and DNA plasmids 
Cells were transiently transfected with 25 nM siRNA (Supplementary Table S2) using the 
HiPerFect (Qiagen) method according to the manufacturer’s directions. DNA and shRNA 
plasmids were transiently transfected using the Effectene (Qiagen) method according to the 
manufacturer’s directions. The MYCN shRNA plasmid was kindly provided by F. Wester-
mann (Neuroblastoma Genetics, DKFZ, Heidelberg, Germany), and the pTER(+) vector [5] 
containing a scrambled shRNA sequence served as control. Applying the GATEWAY tech-
nology (Invitrogen, Darmstadt, Germany), the CD9 sequence was cloned from the gateway 
vector IOH40154 (Invitrogen) into the destination vector pT-REX-DEST30 (Invitrogen) 
(Supplementary Fig. S3C-D). The empty pT-REX-DEST30 vector and the LacZ expression 
vector, pT-REX/GW30/LacZ (Invitrogen), served as controls. The HDAC5-FLAG pcDNA3.1 
plasmid [6] was kindly provided by J. Backs (Cardiac Epigenetics, University Hospital Hei-
delberg, Germany), for which the pcDNA3.1 vector served as a control. To perform anti-
FLAG-GRHL1 ChIP experiments, the GRHL1 sequence was cloned from the destination vec-
tor pT-REX-DEST30 [4] into the destination vector pT-REx™-DEST31 applying the 
GATEWAY technology (Invitrogen).  
Chromatin immunoprecipitation and qPCR 
Cells were lysed for ChIP in buffer containing 50 mM Tris-HCl, 1% SDS, 10 mM EDTA 
and Complete
®
 protease inhibitor cocktail (Roche, Mannheim, Germany), then sonicated to 
obtain chromatin fragments of 100 to 300 base pairs. Anti-MYCN and anti-pan-acetylated 
histone H4 ChIPs were performed according to the ChIP Assay Kit protocol (Merck Milli-
pore). The following antibodies were used: mouse monoclonal anti-MYCN (clone B8.4.B; 
Santa Cruz Biotechnology), rabbit polyclonal anti-pan-acetylated histone H4 (Merck Milli-
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pore) and mouse or rabbit IgG (Santa Cruz Biotechnology) as negative controls. In anti-
FLAG-GRHL1 and anti-HDAC5-FLAG ChIPs, immunocomplexes were captured with anti-
rabbit IgG TrueBlot beads (eBioscience, Frankfurt, Germany) or with anti-FLAG M2-
conjugated agarose (Sigma-Aldrich) by incubation at 4 °C overnight on a rotatory mixer. 
Primers for qRT-PCR amplification of the CD9 promoter region were: 5’-TTTTTAAAAGTGC 
AGCCGGAGA-3’ (forward), 5’-CATCTGTATCCAGCGCCAGG-3’ (reverse). 
Western blotting, immunohistochemistry and flow cytometry 
 Cells were lysed for western blotting in buffer containing 20 mM Tris-HCl, 7 M urea, 
0.01% Triton X-100, 100 mM DTT, 40 mM MgCl2 and Complete
®
 protease inhibitor cocktail 
[7]. The following antibodies were used: mouse monoclonal anti--actin (clone AC-15, Sig-
ma-Aldrich), mouse monoclonal anti-CD9 (clone C-4, Santa Cruz Biotechnology), mouse 
monoclonal anti-GAPDH (clone 6C5, Merck Millipore), rabbit polyclonal anti-GRHL1 (Sig-
ma-Aldrich), rabbit polyclonal anti-HDAC5 (Cell Signaling), rabbit polyclonal anti-histone 
H3 (Cell Signaling) and mouse monoclonal anti-MYCN (clone B8.4.B; Santa Cruz Biotech-
nology). Band density was analyzed using ImageJ 1.47p software [8] on western blots, and 
results were normalized to the respective loading controls. The mouse monoclonal anti-CD9 
antibody (clone C-4, Santa Cruz Biotechnology; [9]) was also used for immunohistochemistry 
on 20 formalin-fixed, paraffin-embedded tumor sections. In brief, tumor sections were freshly 
cut to 4 µm and dried at 80° C for 15 min. CD9-specific immunohistochemistry was per-
formed on an automated immunostainer (Ventana BenchMark XT, Ventana Medical Systems, 
Tucson, AZ) using the OptiView DAB IHC Detection Kit and standard reagents provided by 
Ventana. After completion of the immunohistochemical staining, sections were counter-
stained with hematoxylin to visualize the nuclei in the tumor sections. CD9 protein expression 
in tumor samples was semi-quantitatively analyzed by counting the percentage of CD9-
positive tumor cells and by scoring the staining intensity [10]. Scoring was done in consensus 
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of two investigators. Digitized images were generated using a Leica DMRBE microscope, 
SPOT CCD camera and Software SPOT2.1.2. For anti-CD9 flow cytometry, cells were incu-
bated with 50 µl primary antibody (clone C-4, Santa Cruz Biotechnology) at pretested con-
centration (30 min, 4 °C), washed three times, incubated with dye-labeled secondary antibody 
(30 min, 4 °C) and washed again. Cells were analyzed in a FACScan using the Cell Quest 
analysis program (BD, Heidelberg, Germany). 
Proliferation assay  
Cell viability and number were measured with the VI-CELL Cell Viability Analyzer 
(Beckman, Krefeld, Germany) based on the trypan blue-exclusion method [4].  
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Supplementary Table S1. Primers used in qRT-PCR [4, 11]. 
Gene Forward primer (5’-3’) Reverse primer (5’-3’) Order ID#* 
ACTB GCATCCCCCAAAGTTCACAA AGGACTGGGCCATTC TCCTT  
CD9 GGACGTACTCGAAACCTTCACC GCGGATAGCACAGCA CAAGA  
GRHL1   QT00067025 
HDAC1 TGACGAGTCCTATGAGGCCATT CCGCACTAGGCTGGAACATC  
HDAC2 TGTGAGATTCCCAATGAGTTGC GGTAACATGCGCAAATTTTCAA  
HDAC3 CCTCACTGACCGGGTCATG ACCTGTGCCAGGGAAGAAGTAA  
HDAC4 GAGGTTGAGCGTGAGCAAGAT TAGCGGTGGAGGGACATGTAC  
HDAC5 GTCTCGGCTCTGCTCAGTGTAGA GGCCACTGCGTTGATGTTG  
HDAC6 CAAGGAACACAGTTCACCTTCG GTTCCAAGGCACATTGATGGTA  
HDAC7 AGGACAAGAGCAAGCGAAGTG TTCAGAATCACCTCCGCTAGCT  
HDAC8 CCAAGAGGGCGATGATGATC GTGGCTGGGCAGTCATAACC  
HDAC9 AGTGTGAGACGCAGA CGCTTAG TTTGCTGTCGCATTTGTTCTTT  
HDAC10 ATCTCTTTGAGGATGACCCCAG ACTGCGTCTGCATCTGACTCTC  
HDAC11 CAATGGGCATGAGCGAGAC TGTGGCGGTTGTAGACATCC  
HPRT1 TGACACTGGCAAAACAATGCA GGTCCTTTTCACCAGCAAGCT  
SDHA TGGGAACAAGAGGGCATCTG CCACCACTGCATCAAATTCATG  
18-S   QT00199367  
*
 Qiagen 
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Supplementary Table S2. Purchasing information for siRNAs [4, 11]. 
Gene siRNA abbreviation Company Order ID# 
GRHL1 
si-1 
si-2 
Qiagen 
Qiagen 
SI04251331 
SI04346545 
HDAC1 
si-1 
si-2 
Qiagen  
Qiagen 
SI00070609 
SI00070623 
HDAC2 
si-1 
si-2 
Invitrogen 
Invitrogen 
120209 
120210 
HDAC3 
si-1 
si-2 
Qiagen  
Qiagen 
SI00057337 
SI03057901 
HDAC4 
si-1 
si-2 
Qiagen 
Invitrogen 
SI03082282 
107926 
HDAC5 
si-1 
si-2 
Qiagen 
Qiagen 
SI00077714 
SI00077735 
HDAC6 
si-1 
si-2 
Qiagen 
Qiagen 
SI00084000 
SI04438490 
HDAC7 
si-1 
si-2 
Qiagen 
Qiagen 
SI02777726 
SI04439715 
HDAC8 
si-1 
si-2 
Qiagen 
Qiagen 
SI00122080 
SI03049382 
HDAC9 
si-1 
si-2 
Qiagen 
Qiagen 
SI00148372 
SI00148393 
HDAC11 
si-1 
si-2 
Qiagen 
Qiagen 
SI03039085 
SI03084158 
 siNC-1 Qiagen 1027281 
 siNC-2 Thermo Scientific D-001220-01-20 
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Supplementary Table S3. High-level CD9 mRNA expression in neuroblastomas serves as an 
independent prognostic marker for favorable patient outcome.   
Univariate Cox regression  
 Event-free survival Overall survival 
Factor  n Hazard Ratio 
 (95% CI) 
P Hazard Ratio  
(95% CI) 
P 
CD9 476 0.14 (0.08; 0.24) < 0.001 0.04 (0.02; 0.09) < 0.001 
INSS stage 476  < 0.001  < 0.001 
I, II, III (ref.) 267  -  - 
IV 148 3.96 (2.83; 5.54) - 7.78 (4.83; 12.52) - 
IVs 61 1.18 (0.66; 2.13) - 1.02 (0.39; 2.70) - 
MYCN 471  < 0.001  < 0.001 
Single-copy (ref.) 405  -  - 
Amplified 66 3.68 (2.60; 5.20) - 7.88 (5.29;11.74) - 
Age at diagnosis 476  < 0.001  < 0.001 
≤ 18 months (ref.) 309  -  - 
> 18 months 167 3.49 (2.54; 4.80) - 9.38 (5.75; 15.31) - 
Multivariate Cox regression 
 Event-free survival Overall survival 
Start model n HR (95% CI) P HR (95% CI) P 
CD9 471 0.40 (0.23; 0.72) 0.001 0.36 (0.17; 0.79) 0.005 
INSS stage   0.001  < 0.001 
I, II, III (ref.)   -  - 
IV  2.06 (1.39; 3.05) - 2.84 (1.68, 4.81) - 
IVs  1.50 (0.81; 2.76) - 1.84 (0.66; 5.18) - 
MYCN   0.049  < 0.001 
Single-copy (ref.)   -  - 
Amplified  1.51 (1.01; 2.28) - 2.45 (1.53; 3.93) - 
Age at diagnosis   < 0.001  < 0.001 
≤ 18 months (ref.)   -  - 
> 18 months  2.13 (1.41; 3.20) - 4.14 (2.24; 7.64) - 
      
NOTE: CD9 mRNA expression values were derived from existing whole-genome expression 
profiles of 476 neuroblastoma samples [12]. Univariate and multivariate analyses were per-
formed for EFS and OS using Cox’s proportional hazards regression models. For this pur-
pose, CD9 was scaled with factor 10
-4
 to minimize the wide range of the data. The factors 
CD9 (scaled and continuous), INSS stage (I, II, III (ref.) versus IV versus IVS), MYCN (sin-
gle-copy (ref.) versus amplified) and age at diagnosis (≤ 18 months (ref.) versus > 18 months) 
were fitted into a backward selection. The criterion for inclusion was a likelihood-ratio test p-
value less than 0.05 and for exclusion more than 0.10. Calculations were performed in IBM 
SPSS package (Release 20.0.0) or packages from R version 3.0.1. 
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Supplementary Figure S1. Related to Figure 2. 
Supplementary Figure S2. Related to Figure 2. 
Supplementary Figure S3. Related to Figure 5.  
Supplementary Figure S4. Related to Figure 6. 
Supplementary Figure S5. Related to Figure 6. 
 
Supplementary Figure S1. High-level CD9 expression in neuroblastomas predicts favorable 
patient survival irregardless of age at initial diagnosis. Kaplan-Meier analyses of event-free 
(A-B) and overall survival (C-D).  
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Supplementary Figure S2. High-level CD9 expression in neuroblastomas predicts favorable 
patient survival in the second independent 122-tumor cohort [13] and correlates with favora-
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ble clinical and prognostic markers. Kaplan-Meier analysis shows how CD9 tumor expression 
correlated with event-free (A-B) and overall survival (C-D) irregardless of INSS stage (A, C) 
and in INSS stages 3 and 4 (B, D). Boxplots compared CD9 expression in individual INSS 
stages (E), tumors from patients diagnosed above or under 18 months of age (F), tumors lack-
ing or harboring MYCN amplifications (G) and tumors either lacking or harboring 1p aberra-
tions (H). All analyses were performed in the R2 microarray analysis and visualization plat-
form (http://r2.amc.nl), and the resulting survival curves and P values (log-rank test) were 
downloaded. Cut-off values for separating tumors with high and low levels of CD9 expression 
were also determined using the R2 platform tools. INSS, International Neuroblastoma Staging 
System.  
 
Supplementary Figure S3. HDAC5 negatively regulates endogenous CD9 expression and 
counteracts CD9 induction by panobinostat treatment. CD9 mRNA expression (assessed by 
qRT-PCR) in Kelly (A) and SH-EP cells (B) transfected with HDAC5 or empty vector for 
72h and treated with 15 nM panobinostat or solvent control for 48h. *P < 0.05; **P ≤ 0.01; 
***P ≤ 0.001. 
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Supplementary Figure S4. Characterization of cell models for functional analysis. A-B, CD9 
induction in the stable CD9-inducible SH-EP model. CD9 expression was analyzed at the 
protein level by western blotting (A) and flow cytometry (B) 24-48 hours after treating the 
stable CD9-inducible and control SH-EP clone with 1µg/ml tetracycline. C-D, enforced CD9 
expression in BE(2)-C cells. CD9 expression was analyzed at the protein level by western 
blotting (C) and flow cytometry (D) 24-72 hours after transient transfection with empty- or 
  13 
CD9 vector. Histone H3 served as loading control. Representative blots and images are 
shown.  
 
Supplementary Figure S5. Effect of CD9 expression in neuroblastoma cells on proliferation, 
viability and subcutaneous xenograft growth in mice. A-B, proliferation assay indicating the 
number of viable (A) and dead SH-EP cells (B) 72 hours after induction of CD9 (mean ± SD, 
n = 5). C-D, proliferation assay indicating the number of viable (C) and dead BE(2)-C (D) 
72h after transfection with empty-, LacZ-, or CD9 vector (mean ± SD, n = 5). E, BE(2)-C 
cells were transiently transfected with empty-, LacZ-, or CD9 vector 24h before xenografting 
into CB17-SCID mice. Shown is the time-course of BE(2)-C xenograft growth from the day 
of implantation (day 0) to day 13 (n=12 per study group). n.s., not significant. 
*
P < 0.05. 
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